Outcome of vagus nerve stimulation for epilepsy in Budapest

Katalin Müller, Dániel Fabó, László Entz, A. Kelemen, P. Halász, G. Rásonyi, L. Erőss

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Vagus nerve stimulation (VNS) is a nonpharmacologic therapeutic option for patients with intractable epilepsy. Better clinical outcomes were recorded in nonfocal and Lennox-Gastaut syndrome (LGS). We conducted a 2-year, open label, prospective study to measure the seizure outcome of 26 VNS patients. The seizure numbers were assessed using clinician's global impression scale (CGI) and patient diaries. The average seizure reduction was 23% at the first year and 22% at the second year. Seizure reduction was more pronounced among patients with nonfocal than with focal epilepsy. The response rate was 50% at first year and 30% at the second year. The best CGI record for clinically significant improvement was 15% in the LGS group. The only statistically signifi-cant result was the reduction of the generalized tonic-clonic seizures (GTCS). The side-effect pro-file was good; however, the large number of mild and reversible effects influenced the stimulation parameters and thus probably the effectiveness of the therapy. We suggest that VNS is an optional treatment mostly in cases of therapy-resistant Lennox-Gastaut syndrome. Patients with GTCS may experience improvement such as reduction of seizure severity. We conclude that VNS is a safe neuromodulatory treatment, but future developments of neuromodulatory approaches are needed.

Original languageEnglish
Pages (from-to)98-101
Number of pages4
JournalEpilepsia
Volume51
Issue numberSUPPL. 3
DOIs
Publication statusPublished - Jul 2010

Fingerprint

Vagus Nerve Stimulation
Epilepsy
Seizures
Therapeutics
Partial Epilepsy
Outcome Assessment (Health Care)
Prospective Studies

Keywords

  • Epilepsy
  • Vagal nerve stimulation

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology

Cite this

Outcome of vagus nerve stimulation for epilepsy in Budapest. / Müller, Katalin; Fabó, Dániel; Entz, László; Kelemen, A.; Halász, P.; Rásonyi, G.; Erőss, L.

In: Epilepsia, Vol. 51, No. SUPPL. 3, 07.2010, p. 98-101.

Research output: Contribution to journalArticle

Müller, Katalin ; Fabó, Dániel ; Entz, László ; Kelemen, A. ; Halász, P. ; Rásonyi, G. ; Erőss, L. / Outcome of vagus nerve stimulation for epilepsy in Budapest. In: Epilepsia. 2010 ; Vol. 51, No. SUPPL. 3. pp. 98-101.
@article{7a2a34a4993f4c1782a6a13b8176fb30,
title = "Outcome of vagus nerve stimulation for epilepsy in Budapest",
abstract = "Vagus nerve stimulation (VNS) is a nonpharmacologic therapeutic option for patients with intractable epilepsy. Better clinical outcomes were recorded in nonfocal and Lennox-Gastaut syndrome (LGS). We conducted a 2-year, open label, prospective study to measure the seizure outcome of 26 VNS patients. The seizure numbers were assessed using clinician's global impression scale (CGI) and patient diaries. The average seizure reduction was 23{\%} at the first year and 22{\%} at the second year. Seizure reduction was more pronounced among patients with nonfocal than with focal epilepsy. The response rate was 50{\%} at first year and 30{\%} at the second year. The best CGI record for clinically significant improvement was 15{\%} in the LGS group. The only statistically signifi-cant result was the reduction of the generalized tonic-clonic seizures (GTCS). The side-effect pro-file was good; however, the large number of mild and reversible effects influenced the stimulation parameters and thus probably the effectiveness of the therapy. We suggest that VNS is an optional treatment mostly in cases of therapy-resistant Lennox-Gastaut syndrome. Patients with GTCS may experience improvement such as reduction of seizure severity. We conclude that VNS is a safe neuromodulatory treatment, but future developments of neuromodulatory approaches are needed.",
keywords = "Epilepsy, Vagal nerve stimulation",
author = "Katalin M{\"u}ller and D{\'a}niel Fab{\'o} and L{\'a}szl{\'o} Entz and A. Kelemen and P. Hal{\'a}sz and G. R{\'a}sonyi and L. Erőss",
year = "2010",
month = "7",
doi = "10.1111/j.1528-1167.2010.02620.x",
language = "English",
volume = "51",
pages = "98--101",
journal = "Epilepsia",
issn = "0013-9580",
publisher = "Wiley-Blackwell",
number = "SUPPL. 3",

}

TY - JOUR

T1 - Outcome of vagus nerve stimulation for epilepsy in Budapest

AU - Müller, Katalin

AU - Fabó, Dániel

AU - Entz, László

AU - Kelemen, A.

AU - Halász, P.

AU - Rásonyi, G.

AU - Erőss, L.

PY - 2010/7

Y1 - 2010/7

N2 - Vagus nerve stimulation (VNS) is a nonpharmacologic therapeutic option for patients with intractable epilepsy. Better clinical outcomes were recorded in nonfocal and Lennox-Gastaut syndrome (LGS). We conducted a 2-year, open label, prospective study to measure the seizure outcome of 26 VNS patients. The seizure numbers were assessed using clinician's global impression scale (CGI) and patient diaries. The average seizure reduction was 23% at the first year and 22% at the second year. Seizure reduction was more pronounced among patients with nonfocal than with focal epilepsy. The response rate was 50% at first year and 30% at the second year. The best CGI record for clinically significant improvement was 15% in the LGS group. The only statistically signifi-cant result was the reduction of the generalized tonic-clonic seizures (GTCS). The side-effect pro-file was good; however, the large number of mild and reversible effects influenced the stimulation parameters and thus probably the effectiveness of the therapy. We suggest that VNS is an optional treatment mostly in cases of therapy-resistant Lennox-Gastaut syndrome. Patients with GTCS may experience improvement such as reduction of seizure severity. We conclude that VNS is a safe neuromodulatory treatment, but future developments of neuromodulatory approaches are needed.

AB - Vagus nerve stimulation (VNS) is a nonpharmacologic therapeutic option for patients with intractable epilepsy. Better clinical outcomes were recorded in nonfocal and Lennox-Gastaut syndrome (LGS). We conducted a 2-year, open label, prospective study to measure the seizure outcome of 26 VNS patients. The seizure numbers were assessed using clinician's global impression scale (CGI) and patient diaries. The average seizure reduction was 23% at the first year and 22% at the second year. Seizure reduction was more pronounced among patients with nonfocal than with focal epilepsy. The response rate was 50% at first year and 30% at the second year. The best CGI record for clinically significant improvement was 15% in the LGS group. The only statistically signifi-cant result was the reduction of the generalized tonic-clonic seizures (GTCS). The side-effect pro-file was good; however, the large number of mild and reversible effects influenced the stimulation parameters and thus probably the effectiveness of the therapy. We suggest that VNS is an optional treatment mostly in cases of therapy-resistant Lennox-Gastaut syndrome. Patients with GTCS may experience improvement such as reduction of seizure severity. We conclude that VNS is a safe neuromodulatory treatment, but future developments of neuromodulatory approaches are needed.

KW - Epilepsy

KW - Vagal nerve stimulation

UR - http://www.scopus.com/inward/record.url?scp=77954502570&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77954502570&partnerID=8YFLogxK

U2 - 10.1111/j.1528-1167.2010.02620.x

DO - 10.1111/j.1528-1167.2010.02620.x

M3 - Article

C2 - 20618411

AN - SCOPUS:77954502570

VL - 51

SP - 98

EP - 101

JO - Epilepsia

JF - Epilepsia

SN - 0013-9580

IS - SUPPL. 3

ER -